NextCure and the National Cancer Institute announce

BELTSVILLE, Md., April 19, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel, first-in-class immune medicines to treat cancer and other immune medicines hat-related diseases, announced today the publication of an article titled “Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication” in the Journal of Clinical Investigation.

This paper outlines data from a preclinical study on the influence of collagens in the extracellular matrix (ECM) on tumor immune infiltration, immune cell activation and antitumor responses. The study examined the effect of targeting collagens in the tumor microenvironment (TME) that signal through the inhibitory leukocyte-associated immunoglobin-like receptor-1 (LAIR-1) in combination with targeting of TGF-β and the programmed cell death ligand 1 (PD-). L1) in murine cancer models.

“We are pleased to report that data from our study with the National Cancer Institute (NCI) show that our intervention resulted in reprogramming of suppressive macrophages in the TME, immune activation, enhanced tumor immune infiltration, and high cure rates in mouse models of colon and breast cancer,” said Sol Langermann, Ph.D., NextCure’s chief scientific officer. “By directly targeting components of the ECM and in combination with immune checkpoint blockade therapy, we have demonstrated results superior to either approach alone. We look forward to continuing our research on collagen in the ECM with compounds like NC410.”

In collaboration with the NCI, which is part of the National Institutes of Health, one of Dr. Claudia Palena found that inhibition of TGF-β, PD-L1 and LAIR-1 effectively controls the growth of murine MC38 colon and EMT6 breast carcinomas, two collagen-rich cancers. This inhibition also resulted in tumor cures and long-term tumor-specific protection not achieved with individual compounds by remodeling the tumor’s collagenous matrix, enhancing tumor infiltration, and enhancing CD8 activation+ T cells and repolarizing suppressive macrophage populations.

About NC410
NC410 is a first-in-class immune drug designed to block immunosuppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells, a type of antigen presenting cell. In preclinical research, LAIR-1 has been shown to inhibit T cell function and myeloid activity. In preclinical studies, NC410 blocks the negative effects of LAIR-1 and promotes T cell function and myeloid cell activity. NextCure believes NC410 has the potential to treat multiple types of cancer.

About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel, first-in-class immune medicines for the treatment of cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact on diseases to develop immune drugs. Our initial focus is to bring hope and new treatments to patients who are unresponsive to current cancer therapies, patients whose cancer progresses despite treatment, and patients with cancers not adequately treated by available therapies.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date of this release. Forward-looking statements include statements about NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by the use of forward-looking words such as “may”, “will”, “potential”, “expects”, “believes”, “intends”, “hope”, “towards”, “forward”, “later” and similar expressions. Examples of forward-looking statements in this press release include, but are not limited to, statements regarding the development plans for our immune medicines, statements regarding the progress and assessment and expected timing of results from NextCure’s ongoing NC410 clinical trial, and NextCure’s plans, goals and intentions with respect thereto to the discovery and development of immunomedicine. Forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, among others: the impact of the COVID-19 pandemic on NextCure’s business, including NextCure’s clinical trials, third parties on which NextCure depends, and NextCure’s operations; positive results in pre-clinical studies may not be indicative of clinical study results; limited operational history of NextCure and no products approved for commercial sale; the history of NextCure with significant losses; NextCure’s need for additional funding; risks associated with clinical development, regulatory approval and commercialization; the unproven approach to product candidate discovery and development based on NextCure’s FIND-IO™ platform; and dependence on key personnel. More detailed information about these and other factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including Item 1A of NextCure’s most recent Form 10-K and elsewhere in the company’s records with the SEC. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this press release, and Except as required by law, NextCure undertakes no obligation to update any forward-looking statements, even if expectations change.

investor inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
(240) 762-6486


Leave a Comment